New Signatera™ Data in Lymphoma and Multiple Myeloma to be Presented at the 2025 American Society of Hematology Annual Meeting

Key Terms

circulating tumor DNA medical

Fragments of DNA shed by cancer cells into the bloodstream that act like tiny fingerprints of a tumor; they can be detected with a blood test rather than a biopsy. Investors care because circulating tumor DNA (ctDNA) enables faster, lower-cost ways to detect disease, track treatment response, identify emerging resistance and enroll patients in trials—factors that can materially affect the commercial prospects of diagnostics and therapeutics.

ctDNA medical

Circulating tumor DNA (ctDNA) is tiny fragments of genetic material shed by cancer cells into the bloodstream, like breadcrumbs that can reveal a tumor’s presence and genetic makeup without needing a biopsy. For investors, ctDNA matters because tests and technologies that detect and analyze these fragments can speed diagnosis, track treatment response, and signal relapse, creating commercial opportunities in diagnostics, personalized therapies, and monitoring services.

cell-free DNA medical

Fragments of DNA that float freely in the bloodstream after being released by dying or damaged cells, like puzzle pieces carried downstream that hint at what’s happening upstream. Investors care because measuring these fragments enables non‑invasive tests — for example to detect cancer, monitor treatment response, check pregnancy health, or spot organ rejection — so advances, approvals, or reimbursement changes can quickly affect companies that develop the tests and related technologies.

measurable residual disease medical

Measurable residual disease (MRD) is the tiny number of cancer cells that remain in a patient after treatment and can be detected using sensitive laboratory tests even when scans look clear. For investors, MRD matters because it's a strong early signal of how well a therapy works, can influence clinical trial success, regulatory decisions and future sales, and helps predict whether disease will come back much like spotting embers after a put-out fire.

autologous hematopoietic cell transplant medical

A procedure where a patient’s own blood-forming stem cells are collected, frozen, and later returned after intensive chemotherapy or radiation to rebuild the immune and blood system. Think of it like harvesting seeds from a garden before clearing the plot, then replanting them so new growth can occur. Investors care because it drives demand for specialized drugs, cell-processing services, hospital capacity, and can affect treatment costs, reimbursement and the commercial prospects of related medical products.

CAR-T cell therapy medical

A therapy that takes a patient’s own immune cells, reprograms them in a lab to recognize and attack specific disease cells, then returns them to the body—think of training and equipping a guard dog to find a particular intruder. Investors care because these treatments can offer dramatic clinical benefits, carry high development and manufacturing costs, and create new, often lucrative markets if they receive regulatory approval and payer support.

whole-genome sequencing medical

Whole-genome sequencing is the process of reading an organism’s entire DNA instruction manual to capture all genetic information rather than just selected parts. For investors, it matters because having the full genetic picture can reveal new diagnostics, drug targets, or personalized treatments that drive product value, regulatory approvals, and long-term revenue potential, while improvements in speed and cost can expand market reach like making a complex map easier and cheaper to produce.

whole-exome sequencing medical

Whole-exome sequencing is a laboratory method that reads the portions of an individual’s DNA that directly code for proteins (the exome), which is a small but information-rich slice of the genome. For investors it matters because it’s a faster, cheaper way to find genetic changes linked to disease, guiding diagnostic tests, drug targets and personalized treatments—similar to scanning the most relevant pages of a large manual to find where errors occur.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Largest real-world dataset of personalized circulating tumor DNA (ctDNA) across lymphoma subtypes showed Signatera was prognostic of outcomes and outperformed imaging in detecting recurrence

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, announced that new data on Signatera will be presented at the 2025 American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, Florida. Natera and its collaborators will present four abstracts highlighting the clinical validity and utility of Signatera in hematologic malignancies.

The datasets include an oral presentation on a retrospective real-world cohort evaluating 144 patients across the spectrum of aggressive and indolent lymphomas, suggesting broad clinical applicability of Signatera for treatment response monitoring and end-of-treatment response assessment. Key findings to be presented include:

• Signatera detected recurrence prior to imaging and outperformed standard surveillance methods.
• Personalized ctDNA detection at the end of treatment and on-treatment clearance were strong predictors of clinical outcomes across multiple lymphoma subtypes treated with standard-of-care therapy, including CAR-T cell therapy.
• End-of-treatment assessment with Signatera also helped to clarify ambiguous imaging results, providing important insights for disease management.

This clinical dataset supports the use of Signatera as a response assessment tool in lymphoma, where ctDNA-MRD was incorporated into the NCCN Guidelines in January 2025 for patients with diffuse large B-cell lymphoma.

“The Signatera data at ASH highlights our commitment to advancing precision oncology for patients with blood cancers,” said Alexey Aleshin, M.D., general manager of oncology and corporate chief medical officer at Natera. “The findings from our real-world data reinforce the value Signatera can offer to lymphoma patients for personalized and precise care.”

Full list of presentations include:

December 6, 2:45 PM ET | Presentation # 281 (Oral Presentation)
Presenter: Natalie Galanina, M.D.
Real-world evaluation of ctdna for risk stratification across the spectrum of both aggressive and indolent lymphomas

December 6, 5:30 PM ET | Presentation # 2219
Presenter: Yamuna Kondapally, M.D.
Pilot study of cell-free DNA (cfDNA) for measurable residual disease monitoring following autologous hematopoietic cell transplant in multiple myeloma

December 7, 6:00 PM ET | Presentation # 4353
Presenter: Basem William, M.D., MRCP(UK), FACP
Whole-genome sequencing (WGS)-based circulating tumor DNA (ctDNA) monitoring in diffuse-large B-cell lymphoma (DLBCL)

December 7, 6:00 PM ET | Presentation # 4336
Presenter: Daniel Kerr, M.D.
A novel method for molecular subtyping diffuse-large B-cell lymphoma using whole-exome sequencing

About Natera

Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 325 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251203828324/en/

Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com
Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

Source: Natera, Inc.